This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Rosenberg B, Van Camp L, Grimley EB, Thomson AJ. The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J Biol Chem 1967; 242: 1347-52. PMID: 5337590RosenbergBVanCamp LGrimleyEBThomsonAJThe inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes1967242134752PMID: 533759010.1016/S0021-9258(18)96186-7Search in Google Scholar
Rosenberg B. Van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1969; 222: 385-6. PMID: 5782119RosenbergBVanCamp LTroskoJEMansourVHPlatinum compounds: a new class of potent antitumor agents19692223856PMID: 578211910.1038/222385a05782119Search in Google Scholar
Peyrone M. Über die einwirkungdes ammoniaks auf platichlorür. Annalen der chemie und pharmacie 1844; 51: 1-29. 10.1002/jlac.18440510102PeyroneMÜber die einwirkungdes ammoniaks auf platichlorür18445112910.1002/jlac.18440510102Open DOISearch in Google Scholar
Rosenberg B. Some biological effects of platinum compounds. New agents for the control of tumours. Platinum Met Rev 1971; 15: 42-51.RosenbergBSome biological effects of platinum compounds. New agents for the control of tumours1971154251Search in Google Scholar
Apps MG, Choi EHY, Wheate NJ. The state-of-play and future of platinum drugs. Endocr Relat Cancer 2015; 22: R219-33. 10.1530/ERC-15-0237AppsMGChoiEHYWheateNJThe state-of-play and future of platinum drugs201522R2193310.1530/ERC-15-023726113607Open DOISearch in Google Scholar
Dabrowiak JC. Metals in medicine 2nd edition. John Wiley & Sons Ltd; 2017. p. 94-5.DabrowiakJC2nd editionJohn Wiley & Sons Ltd201794510.1002/9781119191377Search in Google Scholar
Sooriyaarachchi M, Narendran A. Gailer J. Comparative hydrolysis and plasma protein binding of cisplatin and carboplatin in human plasma in vitro. Metallomics 2011; 3: 49-55. 10.1039/c0mt00058bSooriyaarachchiMNarendranAGailerJComparative hydrolysis and plasma protein binding of cisplatin and carboplatin in human plasma in vitro20113495510.1039/c0mt00058b21135941Open DOISearch in Google Scholar
Handing KB, Shabalin IG, Kassaar O, Khazaipoul S, Blindauer CA, Stewart AJ, et al. Circulatory zinc transport is controlled by distinct interdomain sites on mammalian albumins. Chem Sci Chem 2016; 7: 6635-48. 10.1039/c6sc02267gHandingKBShabalinIGKassaarOKhazaipoulSBlindauerCAStewartAJCirculatory zinc transport is controlled by distinct interdomain sites on mammalian albumins2016766354810.1039/c6sc02267g545052228567254Open DOISearch in Google Scholar
Hu W, Luo Q, Wu K, Li X, Wang F, Chen Y, et al. The anticancer drug cisplatin can crosslink the interdomain zinc site on human albumin. Chem Commun (Camb) 2011; 47: 6006-8. 10.1039/c1cc11627dHuWLuoQWuKLiXWangFChenYThe anticancer drug cisplatin can crosslink the interdomain zinc site on human albumin2011476006810.1039/c1cc11627d21526258Open DOISearch in Google Scholar
Martinčič A, Cemazar M, Serša G, Kovač V, Milačič R, Ščančar J. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection. Talanta 2013; 116: 141-8. 10.1016/j.talanta.2013.05.016MartinčičACemazarMSeršaGKovačVMilačičRŠčančarJA novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection2013116141810.1016/j.talanta.2013.05.01624148385Open DOISearch in Google Scholar
Eljack ND, Ma HY, Drucker J, Shen C, Hambley TW, New EJ, et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics 2014; 6: 2126-33. 10.1039/c4mt00238eEljackNDMaHYDruckerJShenCHambleyTWNewEJMechanisms of cell uptake and toxicity of the anticancer drug cisplatin2014621263310.1039/c4mt00238e25306996Open DOISearch in Google Scholar
Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008; 48: 495-535. 10.1146/annurev.pharmtox.48.080907.180426HallMDOkabeMShenDWLiangXJGottesmanMMThe role of cellular accumulation in determining sensitivity to platinum-based chemotherapy20084849553510.1146/annurevpharmtox.48.080907.18042617937596Open DOISearch in Google Scholar
Eljack ND, Ma MH, Drucker J, Shen C, Hambley TW, New JE, et al. Mechanisms of cell uptake and toxicity of the anticancer drug cisplatin. Metallomics 2014; 6: 2126-33. 10.1039/c4mt00238eEljackNDMaMHDruckerJShenCHambleyTWNewJEMechanisms of cell uptake and toxicity of the anticancer drug cisplatin2014621263310.1039/c4mt00238e25306996Open DOISearch in Google Scholar
Lasorsa A, Natile G, Rosato A, Tadini-Buoninsegni F, Arnesano F. Monitoring interactions inside cells by advanced spectroscopies: overview of copper transporters and cisplatin. Curr Med Chem 2018; 25: 462-77. 10.2174/0929867324666171110141311LasorsaANatileGRosatoATadini-BuoninsegniFArnesanoFMonitoring interactions inside cells by advanced spectroscopies: overview of copper transporters and cisplatin2018254627710.2174/092986732466617111014131129121854Open DOISearch in Google Scholar
Holzer AK, Howell SB. The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 2006; 66: 10944-52. 10.1158/0008-5472.CAN-06-1710HolzerAKHowellSBThe internalization and degradation of human copper transporter 1 following cisplatin exposure200666109445210.1158/0008-5472.CAN-06-171017108132Open DOISearch in Google Scholar
Ivy KD, Kaplan JH. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol 2013; 83: 1237-46. 10.1124/mol.113.085068IvyKDKaplanJHA re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells20138312374610.1124/mol.113.085068365710323543413Open DOISearch in Google Scholar
Arnesano F, Seintilla S, Natile G. Interaction between platinum complexes and a methionine motif found in copper transport proteins. Angew Chem Int Ed Engl 2007; 46: 9062-4. 10.1002/anie.200703271ArnesanoFSeintillaSNatileGInteraction between platinum complexes and a methionine motif found in copper transport proteins2007469062410.1002/anie.20070327117886318Open DOISearch in Google Scholar
Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006; 319: 879-86. 10.1124/jpet.106.110346YonezawaAMasudaSYokooSKatsuraTInuiKCisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)20063198798610.1124/jpet.106.11034616914559Open DOISearch in Google Scholar
Nieskens TTG, Peters JGP, Dabaghie D, Korte D, Jansen K, Van Asbeck AH, et al. Expression of organic anion transporter 1 or 3 in human kidney proximal tubule cells reduces cisplatin sensitivity. Drug Metab Dispos 2018; 46: 5929. 10.1124/dmd.117.079384NieskensTTGPetersJGPDabaghieDKorteDJansenKVanAsbeck AHExpression of organic anion transporter 1 or 3 in human kidney proximal tubule cells reduces cisplatin sensitivity201846592910.1124/dmd.117.07938429514829Open DOISearch in Google Scholar
Ciarimboli G. Membrane transporters as mediators of cisplatin side-effects. Anticancer Res 2014; 34: 547-50. PMID: 24403515.CiarimboliGMembrane transporters as mediators of cisplatin side-effects20143454750PMID: 2440351510.6064/2012/473829382046224278698Search in Google Scholar
Calandrini V, Arnesano F, Galliani A, Nguyen TH, Ippoliti E, Carloni P, et al. Platination of the copper transporter ATP7A involved in anticancer drug resistance. Dalton Trans 2014; 43: 12085-94. 10.1039/c4dt01339eCalandriniVArnesanoFGallianiANguyenTHIppolitiECarloniPPlatination of the copper transporter ATP7A involved in anticancer drug resistance201443120859410.1039/c4dt01339e24983998Open DOISearch in Google Scholar
Aggarwal A, Bhatt M. Advances in treatment of Wilson disease. Tremor Other Hyperkinet Mov (NY) 2018; 8: 525. 10.7916/D841881DAggarwalABhattMAdvances in treatment of Wilson disease2018852510.7916/D841881DOpen DOISearch in Google Scholar
Ferreira CR, Gahl WA. Disorders of metal metabolism. Transl Sci Rare Dis 2017; 2: 101-39. 10.3233/TRD-170015FerreiraCRGahlWADisorders of metal metabolism201721013910.3233/TRD-170015Open DOISearch in Google Scholar
Tadini-Buoninsegni F, Bartolommei G, Moncelli MR, Inesi G, Galliani A, Sinisi M, et al. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B. Angew Chem Int Ed Engl 2014; 53: 1297-301. 10.1002/anie.201307718Tadini-BuoninsegniFBartolommeiGMoncelliMRInesiGGallianiASinisiMTranslocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B201453129730110.1002/anie.201307718Open DOISearch in Google Scholar
Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, Igarashi M, et al. Overexpression of metallothionein correlates with chemo resistance to cisplatin and prognosis in oesophageal cancer. Oncology 1997; 54: 342-7. 10.1159/000227714HishikawaYAbeSKinugasaSYoshimuraHMondenNIgarashiMOverexpression of metallothionein correlates with chemo resistance to cisplatin and prognosis in oesophageal cancer199754342710.1159/000227714Open DOISearch in Google Scholar
Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukaemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993; 268: 20116-25. PMID: 8376370.IshikawaTAli-OsmanFGlutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukaemia cells. Molecular characterization of glutathione-platinum complex and its biological significance19932682011625PMID: 837637010.1016/S0021-9258(20)80702-9Search in Google Scholar
Chen HH, Kuo MT. Role of glutathione in the regulation of cisplatin resistance in cancer chemotherapy. Met Based Drugs 2010; pii: 430939. 10.1155/2010/430939ChenHHKuoMTRole of glutathione in the regulation of cisplatin resistance in cancer chemotherapy201043093910.1155/2010/430939294657920885916Open DOISearch in Google Scholar
Sauzay C, White-Koning M, Hennebelle I, Deluche T, Delmas C, Imbs DC, et al. Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin. Pharmacol Res 2016; 110: 89-95. 10.1016/j.phrs.2016.05.012SauzayCWhite-KoningMHennebelleIDelucheTDelmasCImbsDCInhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin2016110899510.1016/j.phrs.2016.05.01227178732Open DOISearch in Google Scholar
Sprowl JA, Ness RA, Sparreboom A. Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet 2013; 28: 19-27. PMID: 22986709SprowlJANessRASparreboomAPolymorphic transporters and platinum pharmacodynamics2013281927PMID: 2298670910.2133/dmpk.DMPK-12-RV-073Search in Google Scholar
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 2009; 86: 396-402. 10.1038/clpt.2009.139FilipskiKKMathijssenRHMikkelsenTSSchinkelAHSparreboomAContribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity20098639640210.1038/clpt.2009.139274686619625999Open DOISearch in Google Scholar
Tzvetkov MV, Behrens G, O’Brien VP, Hohloch K, Brockmöller J, Benöhr P. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics 2011; 12: 1417-27. 10.2217/pgs.11.93TzvetkovMVBehrensGO’BrienVPHohlochKBrockmöllerJBenöhrPPharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms20111214172710.2217/pgs.11.9321902499Open DOISearch in Google Scholar
Hsu CM, Lin PM, Chang JG, Lin HC, Li SH, Lin SF, et al. Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment. Oncotarget 2017; 8: 74348-58. 10.18632/oncotarget.20637HsuCMLinPMChangJGLinHCLiSHLinSFUpregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment20178743485810.18632/oncotarget.20637565034629088791Open DOISearch in Google Scholar
Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D, et al. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J 2009; 9: 127-36. 10.1038/tpj.2008.19ChenYTeranishiKLiSYeeSWHesselsonSStrykeDGenetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function200991273610.1038/tpj.2008.19294906219172157Open DOISearch in Google Scholar
Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111: 1843-50. 10.1289/ehp.6632AuWWSalamaSASierra-TorresCHFunctional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays200311118435010.1289/ehp.6632124174714630517Open DOISearch in Google Scholar
Osawa K. Gene polymorphisms and chemotherapy in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2009; 12: 837-40. 10.3779/j.issn.1009-3419.2009.08.01OsawaKGene polymorphisms and chemotherapy in non-small cell lung cancer2009128374010.3779/jissn.1009-3419.2009.08.0120719167Open DOISearch in Google Scholar
de las Peñas R, Sanchez-Ronco M, Alberola V, Taron M. Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17(4): 668-75. 10.1093/annonc/mdj135de lasPeñas RSanchez-RoncoMAlberolaVTaronMCampsCGarcia-CarboneroRPolymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients20061746687510.1093/annonc/mdj13516407418Open DOISearch in Google Scholar
Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, et al. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 2007; 107(1 Suppl 1): S223-9. 10.1016/j.ygyno.2007.07.024SaldivarJSLuKHLiangDGuJHuangMVlastosATMoving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients20071071 Suppl 1S223910.1016/j.ygyno.2007.07.02417825393Open DOISearch in Google Scholar
Goričar K, Kovač V, Jazbec J, Zakotnik B, Lamovec J, Dolžan V. Genetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma. Cancer Epidemiol 2015; 39: 182-8. 10.1016/j.canep.2014.12.009GoričarKKovačVJazbecJZakotnikBLamovecJDolžanVGenetic variability of DNA repair mechanisms and glutathione-S-transferase genes influences treatment outcome in osteosarcoma201539182810.1016/j.canep.2014.12.00925592234Open DOISearch in Google Scholar
Deng JH, Deng J, Shi DH, Ouyang XN, P.-G. Niu PG. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced nonsmall cell lung cancer patients. Clin Transl Oncol 2015; 17: 720-6. 10.1007/s12094-015-1299-6DengJHDengJShiDHOuyangXNP.-G. NiuPGClinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced nonsmall cell lung cancer patients201517720610.1007/s12094-015-1299-626033426Open DOISearch in Google Scholar
Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, et al. Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumours. Am J Pathol 1996; 148: 877-87. PMID: 8774142.IzquierdoMASchefferGLFlensMJGiacconeGBroxtermanHJMeijerCJBroad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumours199614887787PMID: 8774142Search in Google Scholar
Sedláková I, Laco J, Caltová K, Červinka M, Tošner J, Řezáč A, et al. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer. Int J Gynecol Cancer 2015; 25(2): 236-43. 10.1097/IGC.0000000000000354SedlákováILacoJCaltováKČervinkaMTošnerJŘezáčAClinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer20152522364310.1097/IGC.000000000000035425594141Open DOISearch in Google Scholar
Zhao YN, He DN, Wang YD, Li JJ, Ha MW. Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer. Oncol Lett 2016; 11(4): 2925-33. 10.3892/ol.2016.4311ZhaoYNHeDNWangYDLiJJHaMWAssociation of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer201611429253310.3892/ol.2016.4311481254527073578Open DOISearch in Google Scholar
Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Wasif Saif M. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Metal-Based Drugs 2010; 2010: 1-11. 10.1155/2010/207084MakriliaNSyrigouEKaklamanosIManolopoulosLWasifSaif MHypersensitivity reactions associated with platinum antineoplastic agents: a systematic review2010201011110.1155/2010/207084294565420886011Open DOISearch in Google Scholar
Lafay-Cousin L, Sung L, Carret AS, Hukin J, Wilson B, Johnston DL, et al. Carboplatin hypersensitivity reaction in paediatric patients with low-grade glioma: a Canadian paediatric brain tumour consortium experience. Cancer 2008; 112: 892-9. 10.1002/cncr.23249Lafay-CousinLSungLCarretASHukinJWilsonBJohnstonDLCarboplatin hypersensitivity reaction in paediatric patients with low-grade glioma: a Canadian paediatric brain tumour consortium experience2008112892910.1002/cncr.2324918098210Open DOISearch in Google Scholar
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM Jr, Michelin DP, et al. Single agent carboplatin versus carboplatin plus PEGylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol 2010; 116: 323-5. 10.1016/j.ygyno.2009.11.026MarkmanMMoonJWilczynskiSLopezAMRowlandKM JrMichelinDPSingle agent carboplatin versus carboplatin plus PEGylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial2010116323510.1016/j.ygyno.2009.11.026283616820044128Open DOISearch in Google Scholar
van Meerten E, Franckena M, Wiemer E, van Doorn L, Kraan J, Westermann A, et al. Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area. Oncologist 2015; 20: 241-2. 10.1634/theoncologist.2014-0365vanMeerten EFranckenaMWiemerEvanDoorn LKraanJWestermannAPhase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area201520241210.1634/theoncologist.2014-0365435080025660155Open DOISearch in Google Scholar
Landon CD. Enhancing cisplatin delivery and anti-tumour efficacy using hyperthermia. [Dissertation]. Durcham: Duke University; 2013.LandonCD[Dissertation]. DurchamDuke University2013Search in Google Scholar
Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 3144-53. 10.1056/NEJM199904153401502RosePGBundyBNWatkinsEBThigpenJTDeppeGMaimanMAConcurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer199934031445310.1056/NEJM19990415340150210202165Open DOISearch in Google Scholar
Biston MC, Joubert A, Adam JF, Elleaume H, Bohic S, Charvet AM, et al. Cure of Fisher rats bearing radio resistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-rays. Cancer Res 2004; 64: 2317-23. 10.1158/0008-5472.CAN-03-3600BistonMCJoubertAAdamJFElleaumeHBohicSCharvetAMCure of Fisher rats bearing radio resistant F98 glioma treated with cis-platinum and irradiated with monochromatic synchrotron X-rays20046423172310.1158/0008-5472.CAN-03-3600Open DOISearch in Google Scholar
Coluccia D, Figueiredo CA, Wu MY, Riemenschneider AN, Diaz R, Luck A, et al. Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound. Nanomedicine 2018; 14: 1137-48. 10.1016/j.nano.2018.01.021ColucciaDFigueiredoCAWuMYRiemenschneiderANDiazRLuckAEnhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound20181411374810.1016/jnano.2018.01.02129471172Open DOISearch in Google Scholar
Schumann C, Chan S, Millar JA, Bortnyak Y, Carey K, Fedchyk A, et al. Intraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin. Nanomedicine 2018; 14: 1395-405. 10.1016/j.nano.2018.03.005SchumannCChanSMillarJABortnyakYCareyKFedchykAIntraperitoneal nanotherapy for metastatic ovarian cancer based on siRNA-mediated suppression of DJ-1 protein combined with a low dose of cisplatin201814139540510.1016/j.nano.2018.03.005617410329635082Open DOISearch in Google Scholar
Setua S, Ouberai M, Piccirillo SG, Watts C, Welland M. Cisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma. Nanoscale 2014; 6: 10865-73. 10.1039/c4nr03693jSetuaSOuberaiMPiccirilloSGWattsCWellandMCisplatin-tethered gold nanospheres for multimodal chemo-radiotherapy of glioblastoma20146108657310.1039/c4nr03693j25117686Open DOISearch in Google Scholar
Shahin SA, Wang R, Simargi SI, Glackin CA. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumour burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 2017; 13: 965-76. 10.1016/j.nano.2018.04.00ShahinSAWangRSimargiSIGlackinCAHyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumour burden and enhances sensitivity to cisplatin in ovarian cancer2017139657610.1016/j.nano.2018.04.00Open DOISearch in Google Scholar
Joybari AY, Sarbaz S, Azadeh P, Mirafsharieh SA, Rahbari A, Farasatinasab M, et al. Oxaliplatin-induced renal tubular vacuolization. Ann Pharmacother 2014; 4: 796-800. 10.1177/1060028014526160JoybariAYSarbazSAzadehPMirafshariehSARahbariAFarasatinasabMOxaliplatin-induced renal tubular vacuolization2014479680010.1177/106002801452616024615628Open DOISearch in Google Scholar
Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, et al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009; 101: 37-47. 10.1093/jnci/djn418HellbergVWallinIErikssonSHernlundEJerremalmEBerndtssonMCisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity2009101374710.1093/jnci/djn418263929519116379Open DOISearch in Google Scholar
Hosnedlova B, Kepinska M, Skalickova S, Fernandez C, Ruttkay-Nedecky B, Peng Q, et al. Nano-selenium and its nanomedicine applications: a critical review. Int J Nanomedicine 2018; 13: 2107-28. 10.2147/IJN.S157541HosnedlovaBKepinskaMSkalickovaSFernandezCRuttkay-NedeckyBPengQNano-selenium and its nanomedicine applications: a critical review20181321072810.2147/IJN.S157541590113329692609Open DOISearch in Google Scholar
Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 2005; 25: 3031-40. PMID: 16080562BoulikasTStathopoulosGPVolakakisNVougioukaMSystemic Lipoplatin infusion results in preferential tumor uptake in human studies200525303140PMID: 16080562Search in Google Scholar
Serinan E, Altun Z, Aktaş S, Çeçen E, Olgun N. Comparison of cisplatin with lipoplatin in terms of ototoxicity. J Int Adv Otol 2018; 14: 211-5. 10.5152/iao.2018.4097SerinanEAltunZAktaşSÇeçenEOlgunNComparison of cisplatin with lipoplatin in terms of ototoxicity201814211510.5152/iao.2018.4097635445429460824Open DOISearch in Google Scholar
Serša G, Čemažar M, Miklavčič D. Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice. Cancer Res 1995; 55: 3450-5. PMID: 7614485SeršaGČemažarMMiklavčičDAntitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(II) in mice19955534505PMID: 7614485Search in Google Scholar
Serša G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: Clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863-7. PMID: 107417SeršaGStabucBCemazarMMiklavcicDRudolfZElectrochemotherapy with cisplatin: Clinical experience in malignant melanoma patients200068637PMID: 107417Search in Google Scholar
Gehl J, Sersa G, Wichmann Matthiessen L, Muir T, Soden D, Occhini A, et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 2018, 57: 874-882. 10.1080/0284186X.2018.1454602GehlJSersaGWichmannMatthiessen LMuirTSodenDOcchiniAUpdated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases20185787488210.1080/0284186X.2018.145460229577784Open DOISearch in Google Scholar
Kranjc S, Cemazar M, Sersa G, Scancar J, Grabner S. In vitro and in vivo evaluation of electrochemotherapy with trans-platinum analogue trans-[PtCl2(3-Hmpy)2]. Radiol Oncol 2017; 51: 295-306. 10.1515/raon-2017-0034KranjcSCemazarMSersaGScancarJGrabnerSIn vitro and in vivo evaluation of electrochemotherapy with trans-platinum analogue trans-[PtCl2(3-Hmpy)2]20175129530610.1515/raon-2017-0034561199428959166Open DOISearch in Google Scholar
Grabner S, Modec B, Bukovec N, Bukovec P, Čemažar M, Kranjc S, et al. Cytotoxic trans-platinum(II) complex with 3-hydroxymethylpyridine: Synthesis, X-ray structure and biological activity evaluation. J Inorg Biochem 2016; 161: 40-51. 10.1016/j.jinorgbio.2016.04.031GrabnerSModecBBukovecNBukovecPČemažarMKranjcSCytotoxic trans-platinum(II) complex with 3-hydroxymethylpyridine: Synthesis, X-ray structure and biological activity evaluation2016161405110.1016/j.jinorgbio.2016.04.03127189143Open DOISearch in Google Scholar
Sancho-Martínez SM, Prieto-García L, Prieto M, López-Novoa JM, López-Hernández FJ. Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther 2012; 136: 35-55. 10.1016/j.pharmthera.2012.07.003Sancho-MartínezSMPrieto-GarcíaLPrietoMLópez-NovoaJMLópez-HernándezFJSubcellular targets of cisplatin cytotoxicity: an integrated view2012136355510.1016/j.pharmthera.2012.07.00322796517Open DOISearch in Google Scholar
Rebillard A, Tekpli X, Meurette O, Sergent O, LeMoigne-Muller G, Vernhet L, et al. Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res 2007; 67: 7865-74. 10.1158/0008-5472.CAN-07-0353RebillardATekpliXMeuretteOSergentOLeMoigne-MullerGVernhetLCisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells20076778657410.1158/0008-5472.CAN-07-035317699793Open DOISearch in Google Scholar
Bose RN, Yang WW, Evanics F. Structural perturbation of a C4 zinc-finger module by cis-diamminedichloroplatinum(II): insights into the inhibition of transcription processes by the antitumor drug. Inorganica Chim Acta 2005; 358: 2844-54. org/10.1016/j.ica.2004.06.052BoseRNYangWWEvanicsFStructural perturbation of a C4 zinc-finger module by cis-diamminedichloroplatinum(II): insights into the inhibition of transcription processes by the antitumor drug2005358284454org/10.1016/j.ica.2004.06.052Open DOISearch in Google Scholar
Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H. Combretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action. Bioconjugate Chem 2016; 27: 2132-48. 10.1021/acs.bioconjchem.6b00353HuangXHuangRGouSWangZLiaoZWangHCombretastatin A-4 analogue: a dual-targeting and tubulin inhibitor containing antitumor Pt(IV) moiety with a unique mode of action20162721324810.1021/acs.bioconjchem.6b00353Open DOISearch in Google Scholar
Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloro-platinum(II) metabolism and ATP-dependent efflux from leukaemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993; 268: 20116-25. PMID: 8376370IshikawaTAli-OsmanFGlutathione-associated cis-diamminedichloro-platinum(II) metabolism and ATP-dependent efflux from leukaemia cells. Molecular characterization of glutathione-platinum complex and its biological significance19932682011625PMID: 837637010.1016/S0021-9258(20)80702-9Search in Google Scholar
Hostetter AA, Osborn MF, DeRose VJ. RNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae. ACS Chem Biol 2012; 7: 218-25. 10.1021/cb200279pHostetterAAOsbornMFDeRoseVJRNA-Pt adducts following cisplatin treatment of Saccharomyces cerevisiae201272182510.1021/cb200279pOpen DOISearch in Google Scholar
Wolters DA, Stefanopoulou M, Dyson PJ, Groessl M. Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells. Metallomics 2012; 4: 1185-96. 10.1039/c2mt20070hWoltersDAStefanopoulouMDysonPJGroesslMCombination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells2012411859610.1039/c2mt20070hOpen DOISearch in Google Scholar
Palermo G, Magistrato A, Riedel T, von Erlach T, Davey CA, Dyson PJ, et al. Fighting cancer with transition metal complexes: from naked DNA to protein and chromatin targeting strategies. Chem Med Chem 2016; 11: 1199-210. 10.1002/cmdc.201500478PalermoGMagistratoARiedelTvon ErlachTDaveyCADysonPJFighting cancer with transition metal complexes: from naked DNA to protein and chromatin targeting strategies201611119921010.1002/cmdc.201500478Open DOISearch in Google Scholar
Zou T, Lum CT, Lok CN, Zhang JJ, Che CM. Chemical biology of anticancer gold(III) and gold(I) complexes. Chem Soc Rev 2015; 44: 8786-801. 10.1039/c5cs00132cZouTLumCTLokCNZhangJJCheCMChemical biology of anticancer gold(III) and gold(I) complexes201544878680110.1039/c5cs00132cOpen DOISearch in Google Scholar
Molter A, Kathrein S, Kircher B, Mohr F. Anti-tumour active gold(I), palladium(II) and ruthenium(II) complexes with thio- and selenoureato ligands: a comparative study. Dalton Trans 2018; 47: 5055. 10.1039/C7DT04180BMolterAKathreinSKircherBMohrFAnti-tumour active gold(I), palladium(II) and ruthenium(II) complexes with thio- and selenoureato ligands: a comparative study201847505510.1039/C7DT04180BOpen DOISearch in Google Scholar
Tshuva EY, Miller M. Coordination complexes of titanium(IV) for anticancer therapy. Met Ions Life Sci 2018; 18. 10.1515/9783110470734-014TshuvaEYMillerMCoordination complexes of titanium(IV) for anticancer therapy20181810.1515/9783110470734-014Open DOISearch in Google Scholar
Cini M, Bradshaw TD, Woodward S. Using titanium complexes to defeat cancer: the view from the shoulders of titans. Chem Soc Rev 2017; 4: 1040-51. 10.1039/c6cs00860gCiniMBradshawTDWoodwardSUsing titanium complexes to defeat cancer: the view from the shoulders of titans2017410405110.1039/c6cs00860gOpen DOISearch in Google Scholar
Meléndez E. Titanium complexes in cancer treatment. Crit Rev Oncol Hematol 2002; 42: 309-15. 10.1016/S1040-8428(01)00224-4MeléndezE.Titanium complexes in cancer treatment2002423091510.1016/S1040-8428(01)00224-4Open DOISearch in Google Scholar
Ang DL, Gordon CP, Aldrich-Wright JR. Transition metal intercalators as anticancer agents - recent advances. Int J Mol Sci 2016; 17: 1-17. 10.3390/ijms17111818AngDLGordonCPAldrich-WrightJRTransition metal intercalators as anticancer agents - recent advances20161711710.3390/ijms17111818513381927809241Open DOISearch in Google Scholar